Artelo Biosciences receives USPTO notice of allowance for lead drug
Artelo Biosciences (ARTL) says it receives a Notice of Allowance from the U.S. Patent and Trademark Office for its lead investigational drug currently in two Phase 2 studies.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.